CN107232610A - A kind of carbohydrate composition of beta glucan containing yeast and its application - Google Patents
A kind of carbohydrate composition of beta glucan containing yeast and its application Download PDFInfo
- Publication number
- CN107232610A CN107232610A CN201710376430.7A CN201710376430A CN107232610A CN 107232610 A CN107232610 A CN 107232610A CN 201710376430 A CN201710376430 A CN 201710376430A CN 107232610 A CN107232610 A CN 107232610A
- Authority
- CN
- China
- Prior art keywords
- dextran
- yeast beta
- carbohydrate composition
- containing yeast
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 37
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title abstract description 6
- 229920002498 Beta-glucan Polymers 0.000 title abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 9
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 7
- 239000008101 lactose Substances 0.000 claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 4
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 3
- 229920002307 Dextran Polymers 0.000 claims description 45
- 235000014633 carbohydrates Nutrition 0.000 claims description 31
- 229930091371 Fructose Natural products 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 239000005715 Fructose Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 208000030961 allergic reaction Diseases 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 229960002737 fructose Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001187 pylorus Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000021433 fructose syrup Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100174180 Caenorhabditis elegans fos-1 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of carbohydrate composition containing yeast beta glucan, mainly by yeast beta glucan and oligosaccharide with mass ratio 1：1000~1000：1 combines, wherein oligosaccharide is the one or more in FOS, oligomeric maltose, oligomeric lactose, galactooligosaccharide, xylo-oligosaccharide, and the carbohydrate composition also includes the one or more in monosaccharide and disaccharide, polysaccharide, maltodextrin, glucose polymer；Invention additionally discloses a kind of application of above-mentioned carbohydrate composition in special medicine purposes formula food, wherein the mass fraction of carbohydrate composition is 1% 90%.Yeast beta glucan is nontoxic without allergic reaction, the immunocyte of its special molecular structure energy specific activation body, strengthen body's immunity, carbohydrate composition containing yeast beta glucan can provide energy, strengthen immunity in the preoperative, improve functions of intestines and stomach, being made into formula food is easy to patient to use, and improves its post-operative recovery function.
Description
Technical field
The present invention relates to a kind of composition of carbohydrate, more particularly, to a kind of carbon aquation containing yeast beta-dextran
Polymer composition, while being related to its application in medicinal preparation.
Background technology
Adult's operation consent is in order to reduce the capacity and acidity of gastric content, vomiting and suction, one by mistake during prevention anesthesia
As can fasting 8-12h before surgery, prohibit drink 4h.But preoperative long-time fasting easily causes preoperative ill symptomses, influence tissue to be repaiied
Multiple and wound healing, aggravates postoperative insulin resistance.
For a series of ill symptomses caused by postoperative long-time fasting easily, carbohydrate is drunk within preoperative two hours clear
Liquid has obtained the recommendation of American-European and domestic multinomial authoritative guide, and such as Europe accelerates rehabilitation surgery association, Chinese doctors'associations, Europe
Anaesthetize the parenteral enteral nutrition association of association, anesthetist association of the U.S. and US and European.Research is found, preoperative to drink carbon
Hydrate clear liquid can weaken postoperative insulin resistance, reduce postoperative nitrogen and protein losses, maintain muscular strength, reduction of patient is preoperative
Hungry, thirsty and anxiety, shortens the hospital stays, accelerates Rehabilitation.
The existing carbohydrate clear liquid product of in the market, main composition is glucose syrup, fructose syrup, maltodextrin
Deng being only capable of reaching the effect of simple supplement energy, significant difference had no with supplement glucose solution, clinical value is low.In for example
State patent application CN201510415149.0 discloses a kind of nutritional supplement composition, constitutes as 50-86 parts of maltodextrin, fructose
10-35 parts, 0.188-0.564 parts of sodium, 0.752-1.128 parts of potassium, 0.03-0.075 parts of chlorine, it is seen that its energy extender be malt
Dextrin and fructose, it is only simple that there is the effect for supplementing energy；Chinese patent application CN201610179993.2 discloses a kind of art
Preceding 6-12 parts of tailored version nutritious supplementary pharmaceutical maltodextrin, 1-4 parts of fructose, 1.5-3.5 parts of paddy ammonia phthalein amine, sodium ion 0.025-
0.075 part, 0.06-0.18 parts of potassium ion, are equally to be purely by way of energy extender with maltodextrin and fructose, and it is powder
Shape preparation, it is inconvenient for use；Chinese patent application CN 201610629968.X disclose a kind of compound maltodextrin fructose drink,
Including maltodextrin 100-110g, crystal diabetin 10-20g, sodium citrate 2.0-3.0g, potassium citrate 3.0-4.0g, sweetener
0.1-0.2g, vitamin C 0.2-0.3g, only provide maltodextrin and fructose are used as energy extender.
The content of the invention
Energy can be quickly provided and the carbon of postoperative rehabilitation can be improved in order to solve the above technical problems, present invention offer is a kind of
Hydrate composition.
The technical scheme is that a kind of carbohydrate composition containing yeast beta-dextran is provided, including it is as follows
The component of mass ratio：Yeast beta-dextran:Oligosaccharide=1：1000~1000：1.
Preferably, described yeast beta-dextran and the mass ratio of oligosaccharide are 1：500~500：1.
Preferably, described yeast beta-dextran and the mass ratio of oligosaccharide are 1：100~100：1.
Preferably, described yeast beta-dextran and the mass ratio of oligosaccharide are 1：25~25：1.
The oligosaccharide is one kind in FOS, oligomeric maltose, oligomeric lactose, galactooligosaccharide, xylo-oligosaccharide
Or it is several.
The carbohydrate composition also includes one in monosaccharide and disaccharide, polysaccharide, maltodextrin, glucose polymer
Plant or several.
The monose is the one or more in glucose, fructose, galactolipin；
The disaccharide is the one or more in lactose, sucrose, maltose；
The polysaccharide is the one or more in starch, chitosan.
The present invention provides a kind of carbohydrate composition containing yeast beta-dextran and eaten in special medicine purposes formula
Application in product, the carbohydrate composition containing yeast beta-dextran described in the special medicine purposes formula food
Mass fraction be 1%-90%.
Preferably, the mass fraction of the carbohydrate composition containing yeast beta-dextran is 1%-60%.
Preferably, the mass fraction of the carbohydrate composition containing yeast beta-dextran is 1%-50%.
The special medicine purposes formula food is liquid, facilitates patient to use.
The advantages of the present invention：
Yeast beta-dextran is a kind of polysaccharide being made up of β -1,3 and β -1,6 keys, is extracted by yeast, nontoxic and will not draw
Allergic reaction is played, GRAS products are regarded as by FDA (Food and Drug Adminstration)；As a kind of immunologic stimulant, exempt from very strong
Epidemic disease activity, its special molecular structure can specific activation body immunocyte, so as to strengthen body's immunity, example
Such as, beta glucan can the effective immunocyte such as activated lymphocyte, macrophage, B cell activity；Sent out through zooscopy
Existing, yeast beta-dextran has obvious effect in radioresistance, anti-tumor aspect, is found through human trial, and yeast beta-dextran can
Reduce possibility, influenza decreased duration, the symptom mitigation of influenza virus infection；Carbon hydrate containing yeast beta-dextran
Compositions can provide the function in terms of energy, strengthen immunity, improvement stomach in the preoperative, and being made into formula food can
Facilitate patient to use, improve its post-operative recovery function.
Embodiment
With reference to embodiment, the invention will be further described.
Embodiment 1
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 0.04%, FOS 1%, fructose syrup 40%, citric acid
1%, purified water 57.96%.After each component for weighing above-mentioned mass fraction, mixing is allowed to dispense after being completely dissolved.
Embodiment 2
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 0.1%, oligomeric lactose 10%, maltose 25%, citric acid
2%, purified water 63.9%.After each component for weighing above-mentioned mass fraction, mixing is allowed to dispense after being completely dissolved.
Embodiment 3
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 10%, galactooligosaccharide 5.5%, chitosan 30%, citric acid
1.4%, purified water 54.1%.After each component for weighing above-mentioned mass fraction, mixing is allowed to dispense after being completely dissolved.
Embodiment 4
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 5%, oligomeric maltose 2%, lactose 25%, sucrose 10.5%,
Citric acid 1.5%, purified water 56%.After each component for weighing above-mentioned mass fraction, mixing is allowed to dispense after being completely dissolved.
Embodiment 5
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 0.5%, xylo-oligosaccharide 10%, glucose polymer 30%, fruit
Sugar 5%, citric acid 3%, purified water 51.5%.After each component for weighing above-mentioned mass fraction, mixing is allowed to divide after being completely dissolved
Dress.
Embodiment 6
The present invention provides a kind of special medicine purposes formula food of carbohydrate composition containing yeast beta-dextran
Product, include the component of following mass fraction：Yeast beta-dextran 15%, FOS 5.4%, galactolipin 10%, maltose
20%, citric acid 1.5%, purified water 48.1%.After each component for weighing above-mentioned mass fraction, mixing is allowed to divide after being completely dissolved
Dress.
Embodiment 7
Emptying test
From Kunming germline mouse 50, male and female half and half are divided into five groups, 12h is fasting for solids and liquids before experiment by body weight.Before experiment
2h fill food product of the present invention point low (0.12g/kg), in (0.60g/kg), high (1.20g/kg) three dosage groups, use131Iodine is made
For radionuclide detection Mouse Stomach emptying situation, testing result shows that the gastric emptying half-time of product of the present invention is 45min,
The full emptying time of stomach is 85min, i.e., product of the present invention can be emptied in 2h.
Postoperative energy is supported
From Kunming germline mouse 50, male and female half and half are divided into five groups, 12h is fasting for solids and liquids before experiment by body weight.Experiment is opened
Food following each group medicament is filled during the beginning：Physiological saline blank control group (20mL/Kg)；Chinese patent application CN201610179993.2
Product (2.4mL/Kg) positive controls obtained by embodiment 1；Product of the present invention point low (0.12g/kg), in (0.60g/
Kg), high (1.20g/kg) three dosage groups, the equal gastric infusion of above each group, gavage volume is 0.02mL/g.Fill after food 2h,
Implement mouse orbit rear vein beard measuring blood sugar of blood extracting, insulin, lactic acid index, such as table 1 after general anesthesia, 4h according to body weight.
Table 1
* compared with control group, P<0.05
Postoperative gastroenteritic power is accelerated to recover
From Kunming germline mouse 50, male and female half and half are divided into five groups, 12h is fasting for solids and liquids before experiment by body weight.Experiment is opened
Food following each group medicament is filled during the beginning：Physiological saline blank control group (20mL/Kg)；Chinese patent application CN201610179993.2
Product (2.4mL/Kg) positive controls obtained by embodiment 1；Product of the present invention point low (0.12g/kg), in (0.60g/
Kg), high (1.20g/kg) three dosage groups, the equal gastric infusion of above each group, gavage volume is 0.02mL/g.Fill after food 2h,
Implement each group mouse stomach after general anesthesia, 8h according to body weight and give trophism semisolid paste (sodium carboxymethylcellulose containing 10g, 8g Portugals
Grape sugar, 8g starch is dissolved in 250ml distilled water, adds 0.3mL india ink, stir, and is configured to the black of about 300g
The pasty solid thing of color half), every 0.5mL takes off neck after 20min and put to death, cuts open the belly take full stomach and intestine immediately.It is blind to returning from stomach pylorus
Portion is cut, and is isolated small intestine, is laid on blank sheet of paper.It is placed in 8ml distilled water, is cut off along greater curvature after stomach is separated, is fully washed
Lower gastric content, 3500rpm centrifugations 15min.Pyloric sphincter is measured to pigment foremost and to ileocecus distance, with the two it
Than for alvine pushing rate.Calculation formula is as follows：Alvine pushing rate (%)=pyloric sphincter to pigment distance/pyloric sphincter foremost
To ileocecus distance × 100%.Compared with blank control group and positive controls, basic, normal, high dosage group mouse small intestine propulsion rate
It is improved, illustrates that product of the present invention can improve postoperative gastroenteritic power, promotes physical efficiency recovery, such as table 2：
Table 2
* the P compared with control group<0.05
The present embodiments relate to material, reagent and experimental facilities, be to meet special medical unless otherwise instructed
The commercially available prod in formula food field.
It is described above, only the preferred embodiments of the present invention, it is noted that for those skilled in the art
For, on the premise of the core technology of the present invention is not departed from, improvements and modifications can also be made, these improvements and modifications also should
Belong to the scope of patent protection of the present invention.Any change in the implication and scope suitable with claims of the present invention, all
It is considered as being included within the scope of the claims.
Claims (12)
1. a kind of carbohydrate composition containing yeast beta-dextran, includes the component of following mass ratio：Gather yeast β-Portugal
Sugar:Oligosaccharide=1：1000~1000：1.
2. the carbohydrate composition according to claim 1 containing yeast beta-dextran, it is characterised in that described
The mass ratio of yeast beta-dextran and oligosaccharide is 1：500~500：1.
3. the carbohydrate composition according to claim 1 containing yeast beta-dextran, it is characterised in that described
The mass ratio of yeast beta-dextran and oligosaccharide is 1：100~100：1.
4. the carbohydrate composition according to claim 1 containing yeast beta-dextran, it is characterised in that described
The mass ratio of yeast beta-dextran and oligosaccharide is 1：25~25：1.
5. the carbohydrate composition according to claim 1 containing yeast beta-dextran, it is characterised in that described low
Glycan is the one or more in FOS, oligomeric maltose, oligomeric lactose, galactooligosaccharide, xylo-oligosaccharide.
6. the carbohydrate composition according to claim 1 containing yeast beta-dextran, it is characterised in that the carbon
Hydrate composition also includes the one or more in monosaccharide and disaccharide, polysaccharide, maltodextrin, glucose polymer.
7. the carbohydrate composition according to claim 6 containing yeast beta-dextran, it is characterised in that the list
Sugar is the one or more in glucose, fructose, galactolipin, and the disaccharide is one kind or many in lactose, sucrose, maltose
Kind, the polysaccharide is the one or more in starch, chitosan.
8. the carbohydrate composition containing yeast beta-dextran described in claim 1 is in special medicine purposes formula food
In application.
9. the carbohydrate composition according to claim 8 containing yeast beta-dextran is formulated in special medicine purposes
Application in food, it is characterised in that the mass fraction of the carbohydrate composition containing yeast beta-dextran is
1%-90%.
10. the carbohydrate composition according to claim 8 containing yeast beta-dextran is matched somebody with somebody in special medicine purposes
Application in square food, it is characterised in that the mass fraction of the carbohydrate composition containing yeast beta-dextran is
1%-60%.
11. the carbohydrate composition according to claim 8 containing yeast beta-dextran is matched somebody with somebody in special medicine purposes
Application in square food, it is characterised in that the mass fraction of the carbohydrate composition containing yeast beta-dextran is
1%-50%.
12. the carbohydrate composition according to claim 8 containing yeast beta-dextran is matched somebody with somebody in special medicine purposes
Application in square food, it is characterised in that the special medicine purposes formula food is liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710376430.7A CN107232610A (en) | 2017-05-25 | 2017-05-25 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710376430.7A CN107232610A (en) | 2017-05-25 | 2017-05-25 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107232610A true CN107232610A (en) | 2017-10-10 |
Family
ID=59985670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710376430.7A Pending CN107232610A (en) | 2017-05-25 | 2017-05-25 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107232610A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN109077299A (en) * | 2018-07-26 | 2018-12-25 | 黑龙江省科学院微生物研究所 | A kind of Hericium erinaceus composition and the preparation method and application thereof |
| CN110679931A (en) * | 2019-09-05 | 2020-01-14 | 特素生物科技（天津）有限公司 | Composition suitable for being taken by patient before operation and preparation method thereof |
| WO2020034948A1 (en) * | 2018-08-13 | 2020-02-20 | Lifenergy Biotech Corp. | Method for in vitro activation of immune cells |
| CN111109587A (en) * | 2018-11-01 | 2020-05-08 | 韩连慧 | Food with effects of reducing blood glucose level in human body and enhancing immunity and preparation method thereof |
| CN111227254A (en) * | 2020-02-27 | 2020-06-05 | 赫斯提亚健康科技(无锡)有限公司 | Carbohydrate composition for assisting in reducing blood sugar |
| WO2021222997A1 (en) | 2020-05-05 | 2021-11-11 | Abou Nehmi Filho Victor | Composition for regulating the neuro-immune-endocrine system |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61146192A (en) * | 1984-12-17 | 1986-07-03 | Satoshi Shinohara | Production of culture liquid |
| CN1909914A (en) * | 2004-01-19 | 2007-02-07 | 天然F&P公司 | Novel use of water soluble glucan oligomer isolated from saccharomyces cerevisiae IS2 for prevention and treatment of avian flu |
| CN101940911A (en) * | 2009-07-07 | 2011-01-12 | 上海光明荷斯坦牧业有限公司 | Mycotoxin absorbent compound premix for dairy cows and preparation method thereof |
| CN101972469A (en) * | 2010-08-19 | 2011-02-16 | 天津生机集团股份有限公司 | Immune preparation for aquatic animals |
| CN102257011A (en) * | 2008-12-18 | 2011-11-23 | 格莱科斯芬兰公司 | Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells |
| CN102715236A (en) * | 2012-06-19 | 2012-10-10 | 重庆市天友乳业股份有限公司 | Functional milk and production method thereof |
| CN102907606A (en) * | 2012-11-16 | 2013-02-06 | 西藏天麦力健康品有限公司 | Beta-glucan composition and application thereof |
| CN102919964A (en) * | 2012-11-16 | 2013-02-13 | 西藏天麦力健康品有限公司 | Mixed product comprising beta-glucan and preparation method of mixed product |
| CN104522665A (en) * | 2014-12-30 | 2015-04-22 | 中恩（天津）医药科技有限公司 | Enteral full-nutrition preparation suitable for tumor patients at palliative treatment period and preparation method thereof |
| CN104642870A (en) * | 2015-02-05 | 2015-05-27 | 骆奇 | Prebiotics composition |
| CN104798888A (en) * | 2015-05-08 | 2015-07-29 | 陕西雅泰乳业有限公司 | High-calcium goat milk powder and preparation method thereof |
| CN105124549A (en) * | 2015-07-29 | 2015-12-09 | 广州施健生物科技有限公司 | Nutritional composition for reducing radiation hazards and preparation method thereof |
| CN105211857A (en) * | 2015-09-30 | 2016-01-06 | 广州金酮医疗科技有限公司 | A kind of alimentation composition and uses thereof |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN105707878A (en) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | Full nutrition formulation food for tumors |
| CN105747208A (en) * | 2016-02-23 | 2016-07-13 | 江苏正大丰海制药有限公司 | Oral glucose liquid composition |
| CN105795481A (en) * | 2016-03-24 | 2016-07-27 | 广州军区广州总医院 | Special nutritional supplement agent for preoperative patients |
-
2017
- 2017-05-25 CN CN201710376430.7A patent/CN107232610A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61146192A (en) * | 1984-12-17 | 1986-07-03 | Satoshi Shinohara | Production of culture liquid |
| CN1909914A (en) * | 2004-01-19 | 2007-02-07 | 天然F&P公司 | Novel use of water soluble glucan oligomer isolated from saccharomyces cerevisiae IS2 for prevention and treatment of avian flu |
| CN102257011A (en) * | 2008-12-18 | 2011-11-23 | 格莱科斯芬兰公司 | Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells |
| CN101940911A (en) * | 2009-07-07 | 2011-01-12 | 上海光明荷斯坦牧业有限公司 | Mycotoxin absorbent compound premix for dairy cows and preparation method thereof |
| CN101972469A (en) * | 2010-08-19 | 2011-02-16 | 天津生机集团股份有限公司 | Immune preparation for aquatic animals |
| CN102715236A (en) * | 2012-06-19 | 2012-10-10 | 重庆市天友乳业股份有限公司 | Functional milk and production method thereof |
| CN102907606A (en) * | 2012-11-16 | 2013-02-06 | 西藏天麦力健康品有限公司 | Beta-glucan composition and application thereof |
| CN102919964A (en) * | 2012-11-16 | 2013-02-13 | 西藏天麦力健康品有限公司 | Mixed product comprising beta-glucan and preparation method of mixed product |
| CN104522665A (en) * | 2014-12-30 | 2015-04-22 | 中恩（天津）医药科技有限公司 | Enteral full-nutrition preparation suitable for tumor patients at palliative treatment period and preparation method thereof |
| CN104642870A (en) * | 2015-02-05 | 2015-05-27 | 骆奇 | Prebiotics composition |
| CN104798888A (en) * | 2015-05-08 | 2015-07-29 | 陕西雅泰乳业有限公司 | High-calcium goat milk powder and preparation method thereof |
| CN105124549A (en) * | 2015-07-29 | 2015-12-09 | 广州施健生物科技有限公司 | Nutritional composition for reducing radiation hazards and preparation method thereof |
| CN105211857A (en) * | 2015-09-30 | 2016-01-06 | 广州金酮医疗科技有限公司 | A kind of alimentation composition and uses thereof |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN105747208A (en) * | 2016-02-23 | 2016-07-13 | 江苏正大丰海制药有限公司 | Oral glucose liquid composition |
| CN105795481A (en) * | 2016-03-24 | 2016-07-27 | 广州军区广州总医院 | Special nutritional supplement agent for preoperative patients |
| CN105707878A (en) * | 2016-04-19 | 2016-06-29 | 北京希康宁生物技术有限责任公司 | Full nutrition formulation food for tumors |
Non-Patent Citations (1)
| Title |
|---|
| 何笑丛，等: "β-葡聚糖对代谢综合征的防治作用研究进展", 《中国医药指南》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN109077299A (en) * | 2018-07-26 | 2018-12-25 | 黑龙江省科学院微生物研究所 | A kind of Hericium erinaceus composition and the preparation method and application thereof |
| WO2020034948A1 (en) * | 2018-08-13 | 2020-02-20 | Lifenergy Biotech Corp. | Method for in vitro activation of immune cells |
| CN111109587A (en) * | 2018-11-01 | 2020-05-08 | 韩连慧 | Food with effects of reducing blood glucose level in human body and enhancing immunity and preparation method thereof |
| CN110679931A (en) * | 2019-09-05 | 2020-01-14 | 特素生物科技（天津）有限公司 | Composition suitable for being taken by patient before operation and preparation method thereof |
| CN111227254A (en) * | 2020-02-27 | 2020-06-05 | 赫斯提亚健康科技(无锡)有限公司 | Carbohydrate composition for assisting in reducing blood sugar |
| WO2021222997A1 (en) | 2020-05-05 | 2021-11-11 | Abou Nehmi Filho Victor | Composition for regulating the neuro-immune-endocrine system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107232610A (en) | A kind of carbohydrate composition of beta glucan containing yeast and its application | |
| JP5421512B2 (en) | Use of D-psicose to suppress blood sugar rise | |
| CN106616187A (en) | Solid beverage capable of assisting to lower hypertension, hyperglycemia and hyperlipidemia | |
| CN106135797A (en) | A kind of alimentation composition contributing to regulation blood glucose and preparation method thereof | |
| CN102960520B (en) | L-arabinose health-care press candy added with cyclocarya paliurus | |
| WO2007010976A1 (en) | Body weight gain inhibitory composition comprising d-psicose and use thereof | |
| JP5749880B2 (en) | Body fat accumulation improving agent and metabolic syndrome improving agent comprising D-tagatose as an active ingredient | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| EP0153013A2 (en) | Oral compositions containing dextran | |
| EP4048283A1 (en) | Compositions comprising 2'-fucosyllactose to prevent asthma | |
| CN107213391A (en) | One kind has strengthening spleen and nourishing stomach, and help digestion pharmaceutical composition of tune fat and preparation method thereof | |
| EP2077110A1 (en) | Glutamine-containing composition for increasing blood flow | |
| CN110326793A (en) | A kind of non-wholefood for feeding limited crowd | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| CN110313617A (en) | A kind of aphetite disorder crowd medical usage formula food | |
| CN108904484A (en) | A kind of purposes of progallin A | |
| CN113545479A (en) | Formula food and application thereof | |
| KR101952991B1 (en) | Fat binder obtained from biomass resulting from beer production | |
| CN107853712A (en) | A kind of composition for alleviating hyperglycaemia and preparation method thereof and purposes | |
| CN101959522B (en) | Ketone accumulation inhibitor | |
| CN105494819B (en) | Black tartary buckwheat compound tea beverage and preparation method thereof | |
| CN108925806A (en) | It is a kind of to help the sea cucumber gel drink swallowed and its preparation process and purposes | |
| CN110522022B (en) | Okra powder capable of relaxing bowels and preparation method of okra powder | |
| CN107307252A (en) | A kind of rare sugared function food drink of highland barley monascus and its preparation and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |